Dengue.info

An informational website about dengue
and the Sanofi Pasteur dengue vaccine candidate
For media only

Click the image to see the dengue mosquito, Aedes aegypti in action!

Click image to read From research to phase III

Click image to read Determinants of the Current Dengue Pandemic

Previous Pause Next

Dengue vaccine breakthrough

The Aedes aegypti mosquito, vector of dengue

Working to change the lives of millions

2.5 billion people at risk in over 100 countries

The Philippines: Dengue cases in Iloilo rise to 743

Friday, May 17, 2013
Angola: Country records 197 cases of Dengue in three months

Thursday, May 16, 2013
Indonesia: Jakarta alerted to threat of dengue fever

Thursday, May 16, 2013

Key Phase 3 Study Milestone

Vaccination completed in phase 3 clinical studies of Sanofi Pasteur dengue vaccine candidate READ MORE

Pascal Barollier
Scientific Communications

+33 (0)4 37 37 50 38 media@sanofipasteur.com

ACCESS TO ALL AVAILABLE CONTENT

Sanofi Pasteur Dengue Clinical Studies

Map from DengueWatch.org provided by DVI

Dengue testimonials

Issue 13 | Spotlight on Dengue in the Americas, May 2013
_
READ MORE

Dengue in the Americas: A Growing Public Health Problem that Needs to Be Addressed - Denguematters looks at the increase in the incidence of dengue in the Americas, the challenges of dengue prevention and control, and the critical needs for both now and the future.

September 11, 2012

Sanofi Pasteur Announces Publication in The Lancet of World's First Efficacy Results for its Dengue Vaccine Candidate
July 25, 2012

Sanofi Pasteur's Dengue Vaccine Demonstrates Proof of Efficacy
February 21, 2011

Sanofi Pasteur and International Vaccine Institute Partner Against Dengue

SEE ALL PRESS RELEASES

February 2013

Economic and Disease Burden of Dengue in Southeast Asia
February 2013

Use of Expansion Factors to Estimate the Burden of Dengue in Southeast Asia: A Systematic Analysis
December 2012

Costing Dengue Cases and Outbreaks: A Guide to Current Practices and Procedures

SEE ALL PUBLICATIONS

map

Clinical studies (Jpeg)

Fact Sheet - First Clinical Efficacy Study with Sanofi Pasteur Dengue Vaccine Candidate (Feb 2013)

[pdf - 145 Ko]
Fact Sheet - Sanofi Pasteur Dengue Vaccine Candidate (Oct. 2012)

[pdf - 355 Ko]
Fact Sheet - ASEAN Dengue Day

[PDF - 93 Ko]
Dengue Background Information

[PDF - 95 Ko]

More images on Sanofi Pasteur Flickr

Dengue fever is a mosquito-borne disease caused by four dengue virus serotypes (1 to 4). Overall, the disease is a potential threat to almost half of the world’s population. Of the estimated 100 million people infected annually, 500,000—mostly children—develop dengue hemorrhagic fever (DHF), a severe form of the disease. DHF is a leading cause of hospitalization, placing tremendous pressure on

strained medical resources and having a heavy economic and societal impact.

Many factors have contributed to the re-emergence and dramatic increase in dengue fever including urbanization and increased travel which facilitates dissemination of dengue viruses and the circulation of all four dengue virus serotypes.

Sanofi Pasteur, a world leader in vaccines, has taken on the challenge of providing the first dengue vaccine for individuals living in endemic areas as well as for those who plan to travel to those areas.